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Abstract
Background: Mitochondrial acyl-CoA dehydrogenase family member 9 (ACAD9) is essential for the assembly of
mitochondrial respiratory chain complex I. Disease causing biallelic variants in ACAD9 have been reported in
individuals presenting with lactic acidosis and cardiomyopathy.
Results: We describe the genetic, clinical and biochemical findings in a cohort of 70 patients, of whom 29 previously
unpublished. We found 34 known and 18 previously unreported variants in ACAD9. No patients harbored biallelic loss
of function mutations, indicating that this combination is unlikely to be compatible with life. Causal pathogenic
variants were distributed throughout the entire gene, and there was no obvious genotype-phenotype correlation.
Most of the patients presented in the first year of life. For this subgroup the survival was poor (50% not surviving the
first 2 years) comparing to patients with a later presentation (more than 90% surviving 10 years). The most common
clinical findings were cardiomyopathy (85%), muscular weakness (75%) and exercise intolerance (72%). Interestingly,
severe intellectual deficits were only reported in one patient and severe developmental delays in four patients. More
than 70% of the patients were able to perform the same activities of daily living when compared to peers.
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Conclusions: Our data show that riboflavin treatment improves complex I activity in the majority of patient-derived
fibroblasts tested. This effect was also reported for most of the treated patients and is mirrored in the survival data. In
the patient group with disease-onset below 1 year of age, we observed a statistically-significant better survival for
patients treated with riboflavin.
Keywords: Complex I, Cardiomyopathy, Heart transplantation, Mitochondrial disorder, Lactic acidosis, Treatment,
Prognosis, Neonatal, Vitamin, Activities of daily living
Background
Complex I of the mammalian mitochondrial respiratory
chain is a large multimeric complex composed of 44
subunits encoded by the mitochondrial and nuclear gen-
ome. Beside the structural subunits, at least 19 complex
I specific assembly factors are required to obtain fully
assembled complex I [1].
One assembly factor is ACAD9. Beside its role in the
proper assembly of complex I, ACAD9 exhibits acyl-
CoA dehydrogenase (ACAD) activity [2, 3]. ACADs be-
long to a family of flavoenzymes involved in the ß-oxida-
tion of acyl-CoA and amino acid catabolism. ACAD9 is
most homologous (47% amino acid identity, 65% amino
acid similarity) to very long-chain acyl-CoA dehydrogen-
ase (VLCAD). Both ACAD9 and VLCAD function as
homodimers associated with the inner mitochondrial
membrane and catalyze the initial step of the fatty acid
oxidation (FAO) cycle [4].
Mutations in ACAD9 have been related to human dis-
ease [5–7]. The clinical presentation of ACAD9 deficiency
is dominated by cardiomyopathy. Other features are lactic
acidosis, myopathy and developmental delay. Age of onset,
severity of symptoms and progression are variable. We
have shown that residual ACAD9 enzyme activity, and not
complex I activity, correlates with the severity of clinical
symptoms in ACAD9 deficient patients [3].
In anecdotal reports of patients with a predominance
of myopathic features, alleviation of symptoms under
riboflavin treatment has been reported [5, 7, 8]. Ribofla-
vin is the precursor of flavin adenine dinucleotide (FAD)
and flavin mononucleotide (FMN), which are cofactors
for complex I and numerous dehydrogenases involved in
FAO. The mode of action is unclear, previous studies
suggested that riboflavin increases the mitochondrial
FAD concentration thereby supporting FAD binding and
consecutively improving ACAD9 folding and stability,
thus promoting complex I assembly [9].
Bezafibrate, a peroxisome proliferator-activated recep-
tor (PPAR)-alpha activator that controls the expression
of many FAO genes, has been reported as a potential
treatment for FAO disorders, with beneficial response in
six patients [10]. Recently, this was weakened by a
double-blind randomized crossover study of bezafibrate
in five individuals with acyl-CoA dehydrogenase very
long chain (ACADVL) deficiencies in whom no im-
provement could be detected [11].
In this study, we provide a comprehensive overview of
the clinical, biochemical and genetic spectrum of 70
ACAD9 deficient individuals, of whom 29 are unpub-
lished. We further evaluate the effect of riboflavin in pa-
tients and the effect of riboflavin and bezafibrate
supplementation in patient-derived fibroblast cell lines.
Methods
Individuals
All procedures followed were in accordance with the
ethical standards of the responsible committee on
human experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in
2000. Written informed consent was obtained from all
individuals or caregivers. The clinical data were collected
via an online survey completed by the respective phys-
ician. The online survey included 93 questions regarding
age at presentation, current age or age at death, signs
and symptoms during the fetal and neonatal period, at
the beginning and during the course of disease, circum-
stances of death etc.. A special emphasis lay on the car-
diac and neurological phenotype, daily life activities and
the use of cardiac medication as well as vitmains and
co-factors (e.g. riboflavin).
Kaplan Meier curves were created using the R project
for statistical computing (survival package, https://www.
r-project.org/).
Molecular genetic investigations
Exome sequencing, panel sequencing and Sanger sequen-
cing was performed as described previously [7, 12–22].
Cell culture
Human fibroblast cells were grown in Dulbecco’s modi-
fied Eagle medium-high glucose supplemented with 10%
fetal bovine serum, 1% penicillin-streptomycin (Invitro-
gen) and 200 μM uridine (Sigma-Aldrich) at 37 °C in an
atmosphere containing 5% CO2.
Riboflavin and bezafibrate treatment
The fibroblast cell lines were treated with 400 μM bezafi-
brate, 530 nM riboflavin or vehicle (DMSO) for 72 h as
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previously described [23, 24]. On the second day the cells
were seeded at 20,000 cells/well in 80 μl DMEM in 96 well
cell culture microplate and incubated overnight at 37 °C
and 5% CO2. On the third day of the experiment the
medium was changed to 180 μl unbuffered DMEM and
incubated for at least 30 min at 37 °C without CO2.
Oxygen consumption measurement
Oxygen consumption rate (OCR) was measured using
an XF96 extracellular flux analyzer (Seahorse Biosci-
ences, North Billeric, MA, USA) as previously described
[25, 26] under basal conditions, in the presence of
oligomycin (1 μM, ATP synthase inhibitor), FCCP (0.
4 μM, mitochondrial oxidative phosphorlyation system
(OXPHOS) uncoupler) antimycin A (2.5 μM, complex
III inhibitor) and/or rotenone (0.5 μM, complex-I inhibi-
tor). Antimycin and/or rotenone blocked all mitochon-
drial respiration and were subtracted from all values.
Data was normalized to DNA content with CyQuant
(Invitrogen).
Western blot and BN-PAGE analysis
Western Blot analyses of different proteins were per-
formed according to standard protocols [5, 27] ACAD9,
VLCAD, MCAD, subunits of the respiratory chain com-
plex I (NDUFS1, NDUFA9) and complex II (SDHA)
were investigated and ß-actin was used as a loading con-
trol (Abcam, Sigma-Aldrich, MitoSciences 1:1000).
Electrophoresis and in-gel quantification of fluorescent-
labeled proteins as well as supercomplex assembly are
described in Additional file 1 [28, 29].
Results
Individuals
Seventy individuals (41 females) from 50 families were
recruited, of which 29 were previously unreported
(Additional file 2: Table S1 [30–32] and Additional file 3:
Table S2). Individuals were numbered I1-I70, their re-
spective fibroblast cell lines (if available) accordingly F1-
F70. In the majority of patients investigated (n = 55) a
Fig. 1 ACAD9 mutation status, gene structure and conservation of affected amino acid residues. Gene structure of ACAD9 with localization of
mutations in 70 patients. Blue asterisks indicate splice site mutations. Newly identified mutations are shown in bold. Conservation of amino acid
residues affected by missense variants
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complex I deficiency was found in sceletal (n = 44) or
heart muscle (n = 7) and/or fibroblast cell line (n = 26).
Molecular genetic investigations
Figure 1 and Additional file 2: Table S1 present the 18
previously unreported variants (in bold) and 34 known
variants in ACAD9 found in our cohort. Of these 42
were missense, one frame shift, one nonsense, seven
splice site and one start codon mutation. No individual
harbored two variants predicted to lead to a loss of pro-
tein function.
Based on the prevalence of deleterious ACAD9 alleles
in the normal population (GnomAD, www.gnomad.
broadinstitute.org, [33]) we estimated that approximately
59 children with ACAD9 deficiency will be born each
year in Europe (for calculation see Additional file 3
Table S2).
Clinical spectrum
The data are summarized in Table 1 and Additional file 4:
Table S3. Not all data were available for all patients, the
denominator indicates the number of patients for which
data were available. Currently 37 individuals are alive at
a median age of 14 years (range 24 days – 44 years), the
median age of patients deceased was 3 months (range
1 day – 44 years). Patients with a presentation in the first
year of life (n = 50) show a significantly worse survival when
compared to patients presenting later (n = 20, Fig. 2a). One
individual (I18) was reported with fetal cardiomegaly, two
were reported with fetal rhythm abnormalities, all passed
away early, on day 1 (I18), 2 (I42) and 280 (I55),
respectively.
Cardiomyopathy and treatment
I20 presented with hypertrophic cardiomyopathy in
the first year of life. Due to rapid deterioration, she
received heart transplantation at 2 years. She died of
cardiac failure 4 years later. I21 presented with hyper-
trophic cardiomyopathy at 18 months and subse-
quently developed neurological symptoms (ataxia and
epilepsy), which were non-progressive and mild. She
was successfully heart transplanted at the age of 9
years and is currently 15 years old. I22, currently
35 years old, presented with a progressive biventricu-
lar hypertrophic cardiomyopathy in childhood and
was transplanted at the age of 18 years. After a follow
up of six and 17 years, respectively, their cardiac
function remained satisfactory. I30 showed tachycar-
dia in the first days of life birth and signs of heart
failure at 1 month. Despite undergoing cardioverter-
defibrillator implantation and subsequent heart trans-
plantation, he died at 3 months of age.
Regarding drug treatment, a positive effect on heart
failure was reported for beta-blocking agents (14/44 =
Table 1 Main clinical findings
Number n available Percent
Prenatal findings
Cardiomegaly 1 60 2
Rhythm abnormalities 2 60 3
Decreased child movements 1 60 2
Oligohydramnios 4 60 7
Intrauterine growth failure 6 60 10
Neonatal course
Lactic acidosis 21 63 33
Cardiomyopathy 15 63 24
Rhythm abnormalities 4 54 7
Respiratory failure necessitating
artificial ventilation
6 54 11
Severe liver dysfunction/failure 2 54 4
Severe renal dysfuntion/failure 2 54 4
Most frequent clinical findings
Cardiomyopathy at presentation/
during course
44/56 66/66 67/85
Muscular weakness at presentation/
during course
21/37 48/49 44/75
Exercise intolerance at presentation/
during course
21/34 49/47 43/72
Neurological findings
Severe intellectual disability (clinical
impression)
1 51 2
Mild intellectual disability (clinical
impression)
14 48 29
Severe developmental delay (clinical
impression)
4 52 8
Mild developmental delay (clinical
impression)
23 51 45
Optic atrophy, retinits pigmentosa 0 70 0
Neuroradiological findings
MRI: basal ganglia alterations 4 24 17
MRI: leukoencephalopathy 5 21 24
MRI: global brain atrophy 2 20 10
MRI: isolated cerebellar atrophy 1 20 5
MRS: lactate peak (any location) 2 16 13
Activities of daily living
Age adequate behaviour 27 39 69
Attending/finished regular school 26 41 63
Able to sit independently 34 42 81
Able to walk independently 33 41 80
Able to eat and drink independently 33 41 80
Able to perform personal hygiene
independently
30 41 73
Able to communicate with words/
sentences
34/31 43/42 79/74
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32%), ACE inhibitors (6/40 = 15%), calcium-channel
blockers (1/37 = 3%) and diuretics (3/39 = 8%). No
patient received digitoxin or digoxin. A worsening
effect was only reported for one patient on beta
blockers.
Riboflavin and other oral vitamin treatment
Of the entire cohort of 67 patients, 20 patients were re-
ported as not treated; data about treatment and/or effect
were unavailable for 15 patients. Data on the general
clinical effect of riboflavin as reported by the responsible
physician were available for 31 patients. For 20 patients
(20/31 = 65%) physicians reported a beneficial effect, for
11 (35%) no effect. No clinical deterioration or side ef-
fects were reported. Detailed data on onset of riboflavin
treatment, dosage, duration and clinical effect were only
available for a minority of patients and have not been
investigated.
To analyze the effect of riboflavin treatment, we fo-
cused on the patients presenting during the first year
of life as these was the biggest subgroup and the
group with the shortest survival suggesting the most
severe course. For 39 of these 50 patients, data on
riboflavin treatment were available (n = 17 untreated,
n = 22 treated). Figure 2b shows the Kaplan-Meier
curve for both groups of patients and indicates a sig-
nificantly better survival rate for patients with oral
riboflavin treatment (deceased n = 7/22) in contrast to
untreated patients (deceased n = 16/17).
Regarding other food supplements, several patients
were reported as taking coenzyme Q10, biotin and L-
carnitine with anecdotal positive effects.
Cell culture experiments
Effect of different ACAD9 mutations on ACAD9 protein level
and respiratory chain complex I activity
ACAD9 levels were significantly reduced in all but two
of 14 examined patient fibroblast cell lines; both excep-
tional cell lines (F9, F43) carried a homozygous p.
(Arg518His) variant and showed normal ACAD9 levels
(Fig. 3a).
Complex I-dependent respiration was found to be
significantly decreased in 13 of 17 evaluated patient cell
lines. The cell lines F44 (homozygous p.[Leu98Ser]) and
F12 (homozygous p.[Arg532Trp]) showed no complex I
deficiency; F22 (p.[splice];[Arg433Gln]) and F20 (p.
[Phe120Serfs*9];[Arg532Trp] showed only mildly re-
duced levels (Fig. 3b).
There was no correlation between complex I activity
and residual ACAD9 protein levels. Interestingly, nearly
normal complex I activity was recorded in the cell line
of F42 (p.[Glu564Lys];[Tyr611Cys]) despite very low
steady-state ACAD9 protein levels, indicating that the
c
a
d
b
Fig. 2 Age of onset, causes of death, survival and effect of riboflavin on survival of ACAD9 patients. a Age of onset of symptoms, (b) Causes of
death, (c) Kaplan-Maier survival rates. In red, patients with a disease presentation in the first year of life. In blue, patients with a later presentation
(p = 6.49e-05). b In red, patients with a disease presentation in the first year of life and treated with riboflavin. In blue, patients of the same age
category but untreated with riboflavin (p = 5.34e-05, confidence 95%)
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remaining ACAD9 chaperone activity might be high
enough to correct assembly of complex I (Fig. 3c).
Respiratory chain complex I activity after bezafibrate and
riboflavin supplementation
After 72 h of bezafibrate treatment, the complex I activ-
ity increased in the control and in all but three patients
cell lines. The increase was significant in 12 out of 17
patient cell lines. Five patient cell lines reached almost
normal levels (Fig. 4a). The already normal complex I
activity of two cell lines (F44 and F12) remained
unchanged.
Riboflavin supplementation led to a significant im-
provement of complex I activity in nine out of 15 patient
cell lines and had no effect in the remaining six cell
lines. The increase ranged from 14 to 109% (Fig. 4b).
Supercomplex formation after bezafibrate treatment
All investigated cell lines had a clear reduction of assem-
bled supercomplexes, however, there was no correlation
between the amount of ACAD9 protein and the extent
of supercomplex formation, (e.g. F23 with almost normal
amount of ACAD9 presented a complete loss of super-
complexes whereas F44 with nearly absent ACAD9
protein presented a high amount of assembled super-
complexes). This indicates that small quantities of pro-
ductive ACAD9 can fulfill assembly function. An
increase in the assembly of supercomplexes was found
in four out of five cell lines treated with bezafibrate
(Additional file 5 Figure S1).
Findings in cell culture versus clinical effect in patients
supplemented with riboflavin
The same mutation as in I12/F12 has previously been
reported in I6/F6 (P2 in [7]). I6 was reported to
benefit from oral riboflavin. Both cell lines, F6 and
F12, consequently showed improving complex I activ-
ity under riboflavin treatment (Fig. 3b). Data for treat-
ment of paired cells and patients were only available
for eight patients. In seven pairs the effect was con-
cordant in cells and patients. Six pairs (I/F2, 3, 4, 6,
9, 12) showed positive effects both in cell culture and
Fig. 3 Measurements of ACAD9 protein level and complex I activity in patient derived fibroblasts. a Western blot and quantification of ACAD9
protein levels in patient derived fibroblasts and control. b Complex I activity in patient derived fibroblasts and control. c Comparison between
remaining ACAD9 protein (red) and Complex I activity (blue). Data expressed as average of three independent western blots and average of > 10
technical replicates (oxygen consumption rate ± SD)
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clinical, one pair (I/F44) did not show any response.
I48 did clinically not respond to treatment, whereas
his cells did.
Discussion
Complex I deficiency is the most common biochemical
signature of mitochondrial disorders. Given the number
of ACAD9 deficient patients described here for a dis-
order genetically defined only in 2010, and based on the
frequency of deleterious alleles described to date,
ACAD9 is likely to be one of the more common causes of
mitochondrial respiratory chain deficiency, with a conserva-
tive estimate of 59 new patients born every year in Europe,
and 689 world-wide (Additional file 3 Table S2).
The mutations of the 70 patients from 50 families with
ACAD9 deficiency were located across the coding se-
quence of the gene, with no founder mutations
identified. However, no individual harbored two clear
loss of function alleles, suggesting that a complete loss
of ACAD9 function might be incompatible with life.
This is also supported by the fact that the homozygous
knock out mouse was found to be embryonic lethal
(Schiff, Vockley, personal communication). No genotype-
phenotype correlation for mutations could be identified
based on specific regions of the gene or functional do-
mains of the protein.
The vast majority of patients presented with hyper-
trophic cardiomyopathy, lactic acidosis, muscle weak-
ness, and exercise intolerance. However, patients
without cardiomyopathy also were identified our
study. Although both ACAD9 and VLCAD deficiency
can present with cardiomyopathy, the clinical pheno-
type is otherwise distinct, with hypoglycemia, rhabdo-
myolysis and liver failure, typically seen in VLCAD.
c d
e
a b
Fig. 4 Effect of bezafibrate and riboflavin supplementation on respiratory chain activities in fibroblast cell lines. Maximal oxygen consumption
rate (OCR) was measured in pmol/(s*Mill) of ACAD9 patient and control fibroblasts with and without (a) bezafibrate (400 μM for 72 h) and (b)
riboflavin (530 nM for 72 h) treatment. Data are expressed as the average of > 10 technical replicates and normalized to control. ± SD. ***P <
0.001, **P < 0.01, *P < 0.05. (c) Whole cell lysate of control and different ACAD9 deficient fibroblasts +/− bezafibrate/riboflavin visualized with
antibodies against ACAD9, ACADVL, ACADM, SDHA, ß-actin (loading control), NDUFS1 and NDUFA9 (d, e) Quantification of ACAD9 and ACADVL
protein levels
Repp et al. Orphanet Journal of Rare Diseases  (2018) 13:120 Page 7 of 10
These symptoms were infrequently seen in our
ACAD9 deficient cohort.
Our data suggest, that there are two subgroups of
ACAD9 deficient patients. Patients who presented in the
first year of life often died early and, if surviving, did
more poorly than those who presented later. In contrast
to many other mitochondrial disorders, severe intellec-
tual disability and developmental delay, as well as other
neurological features, were seen in only a minority
of (surviving) patients. Indeed, all patients with se-
vere developmental delay (n = 4) or intellectual delay
(n = 1) had early disease onset. Furthermore, most
patients currently alive were able to perform routine
activities of daily living.
This observation, is not only very important for
providing anticipatory guidance, but might also influ-
ence a decision regarding heart transplantation. Four
patients of our cohort underwent heart transplant-
ation. Unfortunately, the two patients who presented
within the first year died despite all efforts. In con-
trast, the two patients presenting after the age of 1
year developed normally and are currently aged 15
and 35 years, respectively. Additional longitudinal
studies are warranted to better identify which patients
with ACAD9 deficiency are appropriate heart trans-
plant candidates.
Supplementation with riboflavin showed improvement
in complex I activity in the vast majority of patient fibro-
blasts, and most patients similarly were reported to have
clinical benefit with treatment. Most notably, patients
presenting within the first year of life show a significant
better survival when treated with riboflavin. One limita-
tion of this observation could be that most of the deaths
occurred at the end of the first year of life. This might
indicate that our analysis is prone to survivor treatment
selection bias. Detailed data about the starting point of
riboflavin treatment, the dosage etc. in more patients are
needed.
This observation supports anecdotal reports in the
literature. In our cohort, families 1 and 33 are par-
ticularly instructive. In both families the first child
(I1, I45) died within the first 2 years of life without
riboflavin supplementation, whereas the younger af-
fected siblings (I2, I45 and I46), in whom supplemen-
tation was begun immediately upon diagnosis, are
currently still alive (aged 10, 1.5 and 11 years, retro-
spectively). Cases I5 and I6 were first reported with
riboflavin responsive complex I deficiency before their
molecular defect was known [7, 34]. Paired data on
fibroblasts and patient riboflavin treatment were avail-
able for eight patients, six of which showed parallel
beneficial effects and one no effect. Further cellular
studies are necessary to define the mode of action of
riboflavin in ACAD9 deficiency.
The PPAR promotor activator bezafibrate has been
reported to be of benefit in other FAODs. In all cell
lines examined in this study, bezafibrate improved
the formation of respiratory chain super complexes,
likely explaining the improved respiration of the pa-
tient cell lines as measured by whole cell oximetry.
While only a limited number of cell lines were
tested, these results suggest a potential role for
bezafibrate or other PPAR activators in the treat-
ment of ACAD9. However, similar effects for bezafi-
brate have been reported in cell models of other
fatty acid oxidation defects, but were not proven in
humans.
Our retrospective data provides additional descrip-
tion of the clinical and genetic spectrum of ACAD9
deficiency, and provides valuable insight for the devel-
opment of future clinical trials of riboflavin, bezafi-
brate, or other therapies. While the current study was
not designed to be a clinical trial, the anecdotal im-
provement of many ACAD9 deficient patients to ribo-
flavin justifies a trial of riboflavin (20 mg/kg/day,
maximum 200 mg/day) in every patient with this
diagnosis. Given the high frequency of ACAD9 defi-
ciency, we propose that it would be reasonable to
consider riboflavin administration for phenotypically-
consistent patients whilst their genetic investigations
are underway [35]. This also underlines that in pa-
tients with suspicion of a mitochondrial disorder next
generation sequencing techniques should be initiated
promptly, in selected cases accompanied by studies in
affected tissues. For these patients, early diagnosis
and therapeutic intervention could be the difference
between life and death.
Conclusions
ACAD9 typically presents with cardiomyopathy, exercise
intolerance and muscular weakness and the clinical
course might respond to riboflavin.
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Additional file 5: Figure S1. Representative picture of Complex I
assembly in fibroblasts of individual 1 (A, upper panels) Two-dimensional
BN/SDS-PAGE separation and quantification of fluorescent-labelled
mitochondrial complexes from 10 mg patient (left) and control fibroblasts
(right) are shown. (A, lower panels) show silver stained 2 D gels. (B)
Quantified Supercomplexes in 2D gels from control and patient fibroblast
with and without bezafibrate treatment for 72 h. (C) Panoramaplots of 2D
gels with assignment of signals used for quantification of complexes.
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Assignment of complexes: O, OGDC, oxoglutarate dehydrogenase complex; V,
complex V or ATP synthase; III, complex III or cytochrome c reductase; IV,
complex IV or cytochrome c oxidase; S, supercomplexes composed of respiratory
chain complexes I, III, and IV. 2-D gels were scanned side by side for direct
comparison and are shown as pseudocolors. (pdf). (PDF 1109 kb)
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